Drug Discovery & Pharmaceuticals

RSS

The new FlowCam® LO improves particle characterization in drug development

Yokogawa Fluid Imaging Technologies announces the release of the FlowCam® LO, the first and only light obscuration instrument with imaging capabilities.

From Yokogawa Fluid Imaging Technologies, Inc. 29 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Small molecule drug can attenuate the triggers of neuroinflammation, preclinical study shows

Neuroinflammation can worsen outcomes in stroke, traumatic brain injury, or spinal cord injury, as well as accelerate neurodegenerative diseases like ALS, Parkinson's, or Alzheimer's. This suggests that limiting neuroinflammation may represent a promising new approach to treat neurological diseases and neuropathic pain that are driven by neuroinflammation.

24 Sep 2021

Discovery points toward a new strategy for treating Parkinson's disease

University of Utah Health scientists have identified a molecule that slows cells' production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson's disease.

23 Sep 2021

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

A unique type of tiny antibody produced by llamas could provide a new frontline treatment against Covid-19 that can be taken by patients as a simple nasal spray.

22 Sep 2021

Rice bioengineer receives $1.9 million NIH grant to improve time-release drugs

Time-released drugs are about to get a geometry lesson, thanks to bioengineers at Rice University.

21 Sep 2021

Researchers aim to develop edible plant-based mRNA vaccines

The future of vaccines may look more like eating a salad than getting a shot in the arm. UC Riverside scientists are studying whether they can turn edible plants like lettuce into mRNA vaccine factories.

16 Sep 2021

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provide an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.

16 Sep 2021

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors.

13 Sep 2021

Study identifies FDA-approved drugs that are effective in suppressing SARS-CoV-2 replication

Despite the development of SARS-CoV-2 vaccines, effective therapeutics are needed until worldwide immunity has been achieved.

10 Sep 2021

Researchers use amphibian foam to deliver drugs for the first time

Amphibian foam has been used in drug delivery for the first time by researchers, which could help to combat the rise of antimicrobial resistance.

9 Sep 2021

Newly identified mechanism can accelerate the development of STING-activating drugs using imaging

A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging drugs that activate the protein STING, a well-established regulator of immune cell activation, substantially alter the activity of metabolic pathways responsible for generating the nucleotide building blocks for DNA.

7 Sep 2021

Booster shot of Pfizer COVID-19 vaccine provides additional protection against SARS-CoV-2 infection

A team of scientists from the USA and Israel has recently highlighted the importance of a third booster dose of the Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in achieving additional protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server.

2 Sep 2021

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

More than a year after the start of the COVID-19 pandemic, several vaccines have been authorized thanks to unprecedented worldwide research efforts. These first-generation vaccines bring great hope and are a mainstay in fighting the virus.

1 Sep 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

New compounds offer a two-for-one punch to fight estrogen-sensitive breast cancer

A set of compounds developed by scientists at Scripps Research in Florida target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers.

31 Aug 2021

Aston University secures KTP project to assist Catalent in developing orally disintegrating tablets

Aston University researchers based in the College of Health and Life Sciences have been awarded a Knowledge Transfer Partnership (KTP) project by Innovate UK, to bring its academic and scientific expertise to assist Catalent in the development of its Zydis® technology, the leading orally disintegrating tablet (ODT).

27 Aug 2021

Study suggests a balanced approach to developing safer opioid analgesics

Opioids are powerful painkillers but their use is hindered because patients become tolerant to them, requiring higher and higher doses, and overdoses can cause respiratory depression and death.

24 Aug 2021

Peptoids could one day cure or prevent herpes, COVID-19

In addition to antibodies and white blood cells, the immune system deploys peptides to fight viruses and other pathogens.